DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Several other equities research analysts have also recently weighed in on the company. JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th. HC Wainwright lifted their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Trading Down 1.4 %

Shares of NASDAQ DBVT opened at $4.34 on Friday. The business has a 50-day moving average of $3.56 and a 200-day moving average of $3.86. The firm has a market capitalization of $89.27 million, a price-to-earnings ratio of -0.96 and a beta of 0.64. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.49.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Wednesday, November 6th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.90) by $1.10. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.17 million. On average, analysts predict that DBV Technologies will post -7.05 earnings per share for the current year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.